

What patients and caregivers want to happen now: priorities for action

Christoph Thalheim
Secretary General
European MS Platform

Call for action – general issues addressed to regulators


- *Role of patients & care givers as final voice in risk-benefit assessments of new medicines needs to be strengthened further (CHMP representation?)*
- *More frequent interaction between patient groups, health professionals and regulators is needed on benefit-risk discussion and research (good example: EMA survey & workshop in 2009 on ways to improve the EMA information on benefit & risk of medicines)*
- *Better use of dissemination of vital benefit - risk information to the individual patient via patient organisations*

Call for action – specifically on PML

- *Clarification to Tysabri users of the capacity & limitations of blood tests on JCV antibodies as risk indicator*
- *More studies on the – apparently decreasing – risk of developing PML after 3 years of Tysabri use & the 2 years rule*
- *Public private partnership in research on effective anti JC viral therapy (new IMI call is out now...)*
- *Internet based networking of PML patients & care givers to be supported / facilitated (by EMA /FDA/ or MSIF?) and/or*
- *Central database on PML cases to be made available to patients & families once a PML diagnosis is made*

EU & Industry co-funded project European Register for Multiple Sclerosis (EUREMS) 1, 5 Million Euro 2011-2013

- By mid 2014, EUREMS will ...



Thank you!

***Christoph Thalheim
Secretary General
European MS Platform***



christoph.thalheim@emsp.org
www.emsp.org